Biokin/BMS’s Iza-bren Hits First Phase III OS Endpoint, Albeit In China

Esophageal_Cancer
Before the latest announcement, iza-bren had yet to deliver any significant overall survival benefit in any cancer types. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Clinical Trials

More from Immuno-oncology